Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Agenus Inc.NASDAQ: AGEN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $54.48M, compared with -$10.37M a year earlier. Trailing-twelve-month EBITDA was $127.04M.
Context
- EBITDA amounted to 54.5% of revenue in FY2025, down 43.5 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $127.28M (+104.7%) for the fiscal year ending Dec 2026, a slowdown from the +161.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $54.48M+807.4% QoQ
- Last fiscal yearDec 2025
- $62.19M+161.4% YoY
- LTMMar 2026
- $127.04M+256.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +625.3% | +253.4% | -371.8 pp |
| 1 year | +161.4% | +104.7% | -56.7 pp |
| 3-year CAGR | — | +11.7% | — |
| 5-year CAGR | +7.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 62.19M USD
- Year-over-year change
- +161.4%
- 4-year CAGR
- +9.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.19M | +161.4% |
| FY2024 | 2024-12-31 | (101.3M) | +30.6% |
| FY2023 | 2023-12-31 | (145.92M) | +9.8% |
| FY2022 | 2022-12-31 | (161.85M) | -469.7% |
| FY2021 | 2021-12-31 | 43.78M | — |
EBITDA vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 EBITDA of $127.04M is the highest of the 10 companies compared; the peer median is -$104.73M.
- Its year-over-year change of +256.7% is the highest of 9, against a peer median of +15.6%.
- EBITDA amounts to 102.6% of revenue for AGEN, versus a peer median of 874.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.79M | — | — | — |
| LTM Mar 2026 | -$30.19M | -68.1% | — | — | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
| LTM Mar 2026 | -$81.94M | +12.2% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| LTM Mar 2026 | -$107.98M | +49.6% | — | — | |
| LTM Mar 2026 | -$108.82M | +2.8% | — | — | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$130.98M | +37.9% | — | — | |
| Peer median (excluding AGEN) | -$104.73M | +15.6% | — | 874.0% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Cost of Revenue | 182.08M | 197.26M | 237.68M | 156.01M | 80.36M |
| Gross Profit | 113.59M | (99.24M) | (81.37M) | (52.55M) | 33.84M |
| Gross Margin | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| Research & Development | 178.61M | 0 | 234.57M | 155.53M | 0 |
| Selling, General & Admin | 76.36M | 81.01M | 78.74M | 71.88M | 54.39M |
| Operating Expenses | 87.84M | 80.19M | 78.18M | 67.92M | 54.39M |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBITDA | 43.78M | (161.85M) | (145.92M) | (101.3M) | 62.19M |
| EBITDA Margin | 14.8% | -165.1% | -93.4% | -97.9% | 54.5% |
| Operating Income | 25.75M | (179.43M) | (159.55M) | (120.48M) | (20.56M) |
| Operating Margin | 8.7% | -183.0% | -102.1% | -116.4% | -18.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 65.72M | 61.86M | 97.93M | 117.63M | 55.27M |
| Other Income / Expenses | (54.47M) | (51.23M) | (97.89M) | (111.8M) | 17.47M |
| Income Before Tax | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (3.08M) |
| Pre-Tax Margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.93M) | (220.07M) | (245.76M) | (227.21M) | 115K |
| Net Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (Basic) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| EPS (Diluted) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| Weighted Avg Shares | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Weighted Avg Shares (Diluted) | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.